These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17153510)

  • 41. Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents.
    Jones CK; Peters SC; Shannon HE
    Eur J Pain; 2007 Feb; 11(2):208-15. PubMed ID: 16542861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A method for the electromyographic mapping of the detrusor smooth muscle.
    Kinder MV; Gommer ED; Janknegt RA; van Waalwijk van Doorn ES
    Arch Physiol Biochem; 1997 Dec; 105(7):673-90. PubMed ID: 9693714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Demonstration of spontaneous and stretch induced urinary bladder EMG in the living rabbit.
    Kinder MV; Bos R; Janknegt R; Marani E
    Arch Physiol Biochem; 2001 Dec; 109(5):389-403. PubMed ID: 11935379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of 5-HT receptors in treatment of overactive bladder.
    Khaled SM; Elhilali M
    Drugs Today (Barc); 2003 Aug; 39(8):599-607. PubMed ID: 14566383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of serotonin and noradrenaline in stress urinary incontinence.
    Michel MC; Peters SL
    BJU Int; 2004 Jul; 94 Suppl 1():23-30. PubMed ID: 15139860
    [No Abstract]   [Full Text] [Related]  

  • 46. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
    Westanmo AD; Gayken J; Haight R
    Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duloxetine in the treatment of stress urinary incontinence.
    Jost WH; Marsalek P
    Ther Clin Risk Manag; 2005 Dec; 1(4):259-64. PubMed ID: 18360568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
    Lobo ED; Bergstrom RF; Reddy S; Quinlan T; Chappell J; Hong Q; Ring B; Knadler MP
    Clin Pharmacokinet; 2008; 47(3):191-202. PubMed ID: 18307373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems.
    Rueter LE; De Montigny C; Blier P
    J Pharmacol Exp Ther; 1998 May; 285(2):404-12. PubMed ID: 9580577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The predictive value of pre-treatment cystometry in the outcome of women with mixed incontinence treated with duloxetine.
    Vella M; Duckett J; Basu M
    Eur J Obstet Gynecol Reprod Biol; 2010 Aug; 151(2):221-3. PubMed ID: 20434256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats.
    Katoh A; Eigyo M; Ishibashi C; Naitoh Y; Takeuchi M; Ibii N; Ikeda M; Matsushita A
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1067-75. PubMed ID: 7891317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine D(1) and D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test.
    Munro G
    Eur J Pharmacol; 2007 Dec; 575(1-3):66-74. PubMed ID: 17725928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of washing procedure on platelets pretreated with serotonin uptake inhibitors in vitro: low Ki values predict long-lasting inhibition of serotonin uptake in vivo.
    Ishigooka J; Kasahara T; Nagata E; Murasaki M; Miura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):19-21. PubMed ID: 9592808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence.
    Thor KB
    Urology; 2003 Oct; 62(4 Suppl 1):3-9. PubMed ID: 14550831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model.
    Atiemo H; Wynes J; Chuo J; Nipkow L; Sklar GN; Chai TC
    Urology; 2005 Mar; 65(3):622-6. PubMed ID: 15780404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duloxetine: a dual reuptake inhibitor.
    Dugan SE; Fuller MA
    Ann Pharmacother; 2004 Dec; 38(12):2078-85. PubMed ID: 15522980
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain.
    Rueter LE; Kasamo K; de Montigny C; Blier P
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jun; 357(6):600-10. PubMed ID: 9686935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor.
    Engleman EA; Perry KW; Mayle DA; Wong DT
    Neuropsychopharmacology; 1995 Jul; 12(4):287-95. PubMed ID: 7576005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter.
    Troelsen KB; Nielsen EØ; Mirza NR
    Psychopharmacology (Berl); 2005 Oct; 181(4):741-50. PubMed ID: 16032412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.